Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study (vol 113, pg 404, 2021)

Izutsu Koji; Ogura Michinori; Tobinai Kensei; Hatake Kiyohiko; Sakamoto Shigeru; Nishimura Masanori; Hoshino Miyako

首页> 外文期刊>International journal of hematology >Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study (vol 113, pg 404, 2021)

【24h】

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study (vol 113, pg 404, 2021)

机译：Brentuximab Vedotin在日本复发/难治性Hodgkin淋巴瘤或全身性包水性大细胞淋巴瘤中的安全性曲线：营销后监测研究（第113卷，PG 404,2021）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The original article can be found online.

机译：None

著录项

来源
《International journal of hematology》 |2021年第4期|共1页
作者
Izutsu Koji; Ogura Michinori; Tobinai Kensei; Hatake Kiyohiko; Sakamoto Shigeru; Nishimura Masanori; Hoshino Miyako;
展开▼
作者单位

Natl Canc Ctr Dept Hematol Tokyo Japan;

Kasugai Municipal Hosp Dept Hematol Oncol Kasugai Aichi Japan;

Natl Canc Ctr Dept Hematol Tokyo Japan;

Int Univ Hlth &

Welf IUHW Dept Hematol Sch Med Tokyo Japan;

Takeda Pharmaceut Co Ltd Japan Pharma Business Unit Japan Med Off Chuo Ku 1-1 Nihonbashi Honcho;

Takeda Pharmaceut Co Ltd Takeda Dev Ctr Japan Pharmacovigilance Osaka Japan;

Takeda Pharmaceut Co Ltd Japan Pharma Business Unit Japan Med Off Chuo Ku 1-1 Nihonbashi Honcho;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin [J] . Zhi-Gang Cao, Hong-Wei Zhou, Chao-Jin Peng, 癌症（英文版） . 2013,第009期
2. Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin＇s lymphoma [J] . YANG Xi-gui, JIANG Chao 中华医学杂志：英文版 . 2010,第022期
3. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30‐positive Hodgkin's lymphoma or systemic anaplastic large‐cell lymphoma [J] . Dai Maruyama, Hideaki Kagehara, Kenichi Ishizawa, Cancer science. . 2014,第7期

机译：brentuximab vedotin在日本患有复发或难治性CD30阳性霍奇金淋巴瘤或系统间变性大细胞淋巴瘤的患者的I / II期研究
4. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma [J] . Ogura Michinori, Tobinai Kensei, Hatake Kiyohiko, Cancer science. . 2014,第7期

机译：brentuximab vedotin在日本复发或难治性CD30阳性霍奇金淋巴瘤或系统间变性大细胞淋巴瘤患者的I / II期研究
5. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature [J] . Zinzani P. L., Sasse S., Radford J., Critical reviews in oncology/hematology . 2015,第3期

机译：brentuximab vedotin在指定患者计划中的复发/难治性霍奇金淋巴瘤和复发/难治性系统间变性大细胞淋巴瘤的经验：文献综述
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkins lymphoma or systemic anaplastic large-cell lymphoma [O] . Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, 2014

机译：brentuximab vedotin在日本复发或难治性CD30阳性霍奇金淋巴瘤或系统间变性大细胞淋巴瘤患者的I / II期研究
8. A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL) OR R/R HODGKIN LYMPHOMA (HL) [O] . F. Locatelli, C. Mauz-Koerholz, K. Neville, 2017

机译：在复发/难治性（R / R）全身包塑大细胞淋巴瘤（SALCL）或R / R Hodgkin淋巴瘤（HL）中的小儿患者Brentuximab Vedotin的第1/2阶段研究

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study (vol 113, pg 404, 2021)

摘要

著录项

相似文献

相关主题

期刊订阅